pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·3h ago·1 min read
save

Trump administration proposes $70,000 fee to curb foreign student work authorizations

Oct 13, 2026·read at STAT ↗RegulatoryNegative

The Department of Homeland Security announced a proposed $70,000 fee for a work authorization program that many foreign students and scholars use to gain professional experience in the United States.

The proposal was part of a pair of sweeping announcements issued within two days, aimed at tightening restrictions on international researchers who comprise a sizable share of the nation’s biomedical research workforce.

If implemented, the high cost could limit the ability of foreign students to obtain the authorizations needed for training and research positions, potentially affecting the pipeline of talent that supports U.S. biotech and pharmaceutical development.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “How many ways can the Trump administration clamp down on international researchers?”

read at STAT ↗
1,332 words · retrieved 2h ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
Gossamer Bio, Inc.NEUROCRINENEUROCRINE BIOSCIENCES INCUltragenyx Pharmaceutical Inc.
drugs
Rare Disease
topics
Vaccines3Oncology2Rare Disease

related stories

  • Aug 14STAT+: FDA approves Bristol multiple myeloma treatment, marking debut of novel drug classSTAT
  • Aug 13STAT+: Eli Lilly targets booming black market for retatrutideSTAT
  • Aug 13STAT+: Neurocrine Biosciences and the delicate balance of benefit and riskSTAT
  • Aug 12STAT+: Definium Therapeutics says its LSD therapy eased anxiety in late-stage trialSTAT
  • Aug 12STAT+: Biotech company co-founded by top autoimmune researcher lays out plans with antibody therapiesSTAT